Kodiak Sciences Inc (KOD)
Healthcare
Biotechnology
41.60 $
-2.2%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Kodiak Sciences Inc (KOD)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 62.8% of the shares are freely tradable; institutional investors hold 99.6%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
99.6%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
5.2%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
62.8%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
26.4%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
63Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Baker Bros Advisors LP | 31.83 | 19,919,186 | +0.0 | 03/31/2026 |
| BlackRock Inc | 6.29 | 3,935,302 | -0.5 | 03/31/2026 |
| State Street Corp | 3.60 | 2,250,920 | +30.0 | 03/31/2026 |
| T. Rowe Price Associates, Inc. | 3.26 | 2,039,350 | +74.3 | 03/31/2026 |
| BRAIDWELL LP | 2.91 | 1,818,665 | -12.3 | 03/31/2026 |
| Vanguard Capital Management, LLC | 2.74 | 1,717,076 | +0.0 | 03/31/2026 |
| The Goldman Sachs Group Inc | 2.70 | 1,689,003 | +29.6 | 03/31/2026 |
| RTW INVESTMENTS, LLC | 2.38 | 1,487,934 | +0.0 | 03/31/2026 |
| TCG Crossover Management, LLC | 2.31 | 1,445,538 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 2.35 | 1,468,710 | -1.0 | 07/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.